Child/Adolescent Anxiety Multimodal Study (CAMS): rationale, design, and methods
- PMID: 20051130
- PMCID: PMC2818613
- DOI: 10.1186/1753-2000-4-1
Child/Adolescent Anxiety Multimodal Study (CAMS): rationale, design, and methods
Abstract
Objective: To present the design, methods, and rationale of the Child/Adolescent Anxiety Multimodal Study (CAMS), a recently completed federally-funded, multi-site, randomized placebo-controlled trial that examined the relative efficacy of cognitive-behavior therapy (CBT), sertraline (SRT), and their combination (COMB) against pill placebo (PBO) for the treatment of separation anxiety disorder (SAD), generalized anxiety disorder (GAD) and social phobia (SoP) in children and adolescents.
Methods: Following a brief review of the acute outcomes of the CAMS trial, as well as the psychosocial and pharmacologic treatment literature for pediatric anxiety disorders, the design and methods of the CAMS trial are described.
Results: CAMS was a six-year, six-site, randomized controlled trial. Four hundred eighty-eight (N = 488) children and adolescents (ages 7-17 years) with DSM-IV-TR diagnoses of SAD, GAD, or SoP were randomly assigned to one of four treatment conditions: CBT, SRT, COMB, or PBO. Assessments of anxiety symptoms, safety, and functional outcomes, as well as putative mediators and moderators of treatment response were completed in a multi-measure, multi-informant fashion. Manual-based therapies, trained clinicians and independent evaluators were used to ensure treatment and assessment fidelity. A multi-layered administrative structure with representation from all sites facilitated cross-site coordination of the entire trial, study protocols and quality assurance.
Conclusions: CAMS offers a model for clinical trials methods applicable to psychosocial and psychopharmacological comparative treatment trials by using state-of-the-art methods and rigorous cross-site quality controls. CAMS also provided a large-scale examination of the relative and combined efficacy and safety of the best evidenced-based psychosocial (CBT) and pharmacologic (SSRI) treatments to date for the most commonly occurring pediatric anxiety disorders. Primary and secondary results of CAMS will hold important implications for informing practice-relevant decisions regarding the initial treatment of youth with anxiety disorders.
Trial registration: ClinicalTrials.gov NCT00052078.
Figures
Comment in
-
The importance of the discourse on the method.Child Adolesc Psychiatry Ment Health. 2010 Jan 7;4:2. doi: 10.1186/1753-2000-4-2. Child Adolesc Psychiatry Ment Health. 2010. PMID: 20150989 Free PMC article. No abstract available.
Similar articles
-
24- and 36-week outcomes for the Child/Adolescent Anxiety Multimodal Study (CAMS).J Am Acad Child Adolesc Psychiatry. 2014 Mar;53(3):297-310. doi: 10.1016/j.jaac.2013.11.010. Epub 2013 Nov 28. J Am Acad Child Adolesc Psychiatry. 2014. PMID: 24565357 Free PMC article. Clinical Trial.
-
Child/Adolescent anxiety multimodal study: evaluating safety.J Am Acad Child Adolesc Psychiatry. 2015 Mar;54(3):180-90. doi: 10.1016/j.jaac.2014.12.015. Epub 2014 Dec 31. J Am Acad Child Adolesc Psychiatry. 2015. PMID: 25721183 Free PMC article. Clinical Trial.
-
Remission after acute treatment in children and adolescents with anxiety disorders: findings from the CAMS.J Consult Clin Psychol. 2011 Dec;79(6):806-13. doi: 10.1037/a0025933. J Consult Clin Psychol. 2011. PMID: 22122292 Free PMC article. Clinical Trial.
-
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217. Cochrane Database Syst Rev. 2022. PMID: 36321557 Free PMC article.
-
Treatment of Anxiety Disorders: A Systematic Review [Internet].Stockholm: Swedish Council on Health Technology Assessment (SBU); 2005 Nov. SBU Yellow Report No. 171/1+2. Stockholm: Swedish Council on Health Technology Assessment (SBU); 2005 Nov. SBU Yellow Report No. 171/1+2. PMID: 28876726 Free Books & Documents. Review.
Cited by
-
The therapeutic relationship in cognitive-behavioral therapy and pharmacotherapy for anxious youth.J Consult Clin Psychol. 2013 Oct;81(5):859-64. doi: 10.1037/a0033294. Epub 2013 Jun 10. J Consult Clin Psychol. 2013. PMID: 23750468 Free PMC article. Clinical Trial.
-
The child anxiety impact scale: examining parent- and child-reported impairment in child anxiety disorders.J Clin Child Adolesc Psychol. 2014;43(4):579-91. doi: 10.1080/15374416.2013.817311. Epub 2013 Aug 5. J Clin Child Adolesc Psychol. 2014. PMID: 23915200 Free PMC article.
-
The Effects of Youth Anxiety Treatment on School Impairment: Differential Outcomes Across CBT, Sertraline, and their Combination.Child Psychiatry Hum Dev. 2019 Dec;50(6):940-949. doi: 10.1007/s10578-019-00896-3. Child Psychiatry Hum Dev. 2019. PMID: 31087216
-
Clinical assessment of DSM-IV anxiety disorders in fragile X syndrome: prevalence and characterization.J Neurodev Disord. 2011 Mar;3(1):57-67. doi: 10.1007/s11689-010-9067-y. Epub 2010 Dec 3. J Neurodev Disord. 2011. PMID: 21475730 Free PMC article.
-
Predictors and moderators of treatment response in childhood anxiety disorders: results from the CAMS trial.J Consult Clin Psychol. 2014 Apr;82(2):212-24. doi: 10.1037/a0035458. Epub 2014 Jan 13. J Consult Clin Psychol. 2014. PMID: 24417601 Free PMC article. Clinical Trial.
References
-
- Ezpeleta L, Keeler G, Erkanli A, Costello EJ, Angold A. Epidemiology of psychiatric disability in childhood and adolescence. Journal of Child Psychology & Psychiatry & Allied Disciplines. 2001;42:901–914. - PubMed
-
- Albano AM, Chorpita BF, Barlow DH. Child psychopathology. 2. New York, NY: Guilford Press; 2003. Childhood anxiety disorders; pp. 279–329.